15 February 2022 - Pfizer and OPKO Health announced today that the European Commission has granted marketing authorisation for the next generation long-acting recombinant human growth hormone Ngenla (somatrogon), a once weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.
Ngenla provides paediatric patients, their caregivers and health care providers with a new treatment option for growth hormone deficiency that reduces the frequency of required injections from once daily to once weekly.